179 related articles for article (PubMed ID: 33284639)
1. Self-monitoring with home based fecal calprotectin is associated with increased medical treatment. A randomized controlled trial on patients with inflammatory bowel disease.
Östlund I; Werner M; Karling P
Scand J Gastroenterol; 2021 Jan; 56(1):38-45. PubMed ID: 33284639
[TBL] [Abstract][Full Text] [Related]
2. Real-life utility and diagnostic accuracy of a home-performed fecal calprotectin test to predict endoscopic activity in patients with inflammatory bowel disease under maintenance treatment with adalimumab.
Orfanoudaki E; Drygiannakis I; Theodoraki E; Foteinogiannopoulou K; Mantaka A; Koutroubakis IE
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e777-e782. PubMed ID: 34284415
[TBL] [Abstract][Full Text] [Related]
3. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial.
Ankersen DV; Weimers P; Marker D; Bennedsen M; Saboori S; Paridaens K; Burisch J; Munkholm P
World J Gastroenterol; 2019 Oct; 25(40):6158-6171. PubMed ID: 31686770
[TBL] [Abstract][Full Text] [Related]
4. Is home monitoring of inflammatory bowel disease feasible? A randomized controlled study.
Puolanne AM; Kolho KL; Alfthan H; Färkkilä M
Scand J Gastroenterol; 2019 Jul; 54(7):849-854. PubMed ID: 31264494
[No Abstract] [Full Text] [Related]
5. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease.
Rosenfeld G; Greenup AJ; Round A; Takach O; Halparin L; Saadeddin A; Ho JK; Lee T; Enns R; Bressler B
World J Gastroenterol; 2016 Sep; 22(36):8211-8. PubMed ID: 27688663
[TBL] [Abstract][Full Text] [Related]
6. Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity.
Heida A; Knol M; Kobold AM; Bootsman J; Dijkstra G; van Rheenen PF
Clin Gastroenterol Hepatol; 2017 Nov; 15(11):1742-1749.e2. PubMed ID: 28606846
[TBL] [Abstract][Full Text] [Related]
7. A Web-Based Telemanagement System for Improving Disease Activity and Quality of Life in Patients With Complex Inflammatory Bowel Disease: Pilot Randomized Controlled Trial.
Del Hoyo J; Nos P; Faubel R; Muñoz D; Domínguez D; Bastida G; Valdivieso B; Correcher M; Aguas M
J Med Internet Res; 2018 Nov; 20(11):e11602. PubMed ID: 30482739
[TBL] [Abstract][Full Text] [Related]
8. Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease.
Gauss A; Geiss T; Hinz U; Schaefert R; Zwickel P; Zawierucha A; Stremmel W; Klute L
Medicine (Baltimore); 2016 Apr; 95(16):e3477. PubMed ID: 27100452
[TBL] [Abstract][Full Text] [Related]
9. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
Dig Dis Sci; 2017 Nov; 62(11):3123-3130. PubMed ID: 28948412
[TBL] [Abstract][Full Text] [Related]
10. The Accuracy of a Home-performed Faecal Calprotectin Test in Paediatric Patients With Inflammatory Bowel Disease.
Lerchova T; Hradsky O; Copova I; Potuznikova K; Gonsorcikova L; Bronsky J
J Pediatr Gastroenterol Nutr; 2019 Jul; 69(1):75-81. PubMed ID: 30908389
[TBL] [Abstract][Full Text] [Related]
11. Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring.
Wei SC; Tung CC; Weng MT; Wong JM
Intest Res; 2018 Oct; 16(4):546-553. PubMed ID: 30301339
[TBL] [Abstract][Full Text] [Related]
12. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
Mirsepasi-Lauridsen HC; Bachmann Holmetoft U; Ingdam Halkjær S; Angeliki Krogfelt K; Munk Petersen A
Scand J Gastroenterol; 2016; 51(2):211-7. PubMed ID: 26359672
[TBL] [Abstract][Full Text] [Related]
13. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
[TBL] [Abstract][Full Text] [Related]
14. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity.
Lee YW; Lee KM; Lee JM; Chung YY; Kim DB; Kim YJ; Chung WC; Paik CN
Korean J Intern Med; 2019 Jan; 34(1):72-80. PubMed ID: 29347813
[TBL] [Abstract][Full Text] [Related]
15. Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children.
Krzesiek E
Adv Clin Exp Med; 2015; 24(5):815-22. PubMed ID: 26768632
[TBL] [Abstract][Full Text] [Related]
16. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease.
Hoekman DR; Diederen K; Koot BG; Tabbers MM; Kindermann A; Benninga MA
Eur J Pediatr; 2016 Oct; 175(10):1335-42. PubMed ID: 27573259
[TBL] [Abstract][Full Text] [Related]
17. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
18. Can 2 Different Fecal Calprotectin Assays be Used Interchangeably in IBD Treatment?
van Wassenaer EA; Diederen K; van Leeuwen EMM; D'Haens GR; Benninga MA; Koot BGP; Kindermann A
J Clin Gastroenterol; 2022 Jan; 56(1):e27-e30. PubMed ID: 33116067
[TBL] [Abstract][Full Text] [Related]
19. The IBD-FITT study - moderate-intensity exercise for patients with inflammatory bowel disease with moderate disease activity: an open-label randomized controlled trial.
Lund K; Knudsen T; Kjeldsen J; Nielsen RG; Juhl CB; Nørgård BM
Trials; 2023 Nov; 24(1):742. PubMed ID: 37986021
[TBL] [Abstract][Full Text] [Related]
20. Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial.
Heida A; Dijkstra A; Groen H; Muller Kobold A; Verkade H; van Rheenen P
Trials; 2015 Jun; 16():271. PubMed ID: 26073770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
